Observational studyRMD open2025

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study.

Alp Temiz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.